A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV

Phase 1 Completed 24 enrolled University of Oxford Centre Hospitalier Universitaire Le Dantec, Dakar, Senegal · collab

Non-randomizedSingle-groupOpen-labelPrevention

Summary

This is an open Phase I study of a candidate TB vaccine, MVA85A, in healthy subjects who are infected with HIV. It is designed to study the safety and immunogenicity of the vaccine.

Timeline

Start: 2008-08
Primary completion: 2011-01
Completion: 2011-01

Publications

Dieye TN, Ndiaye BP, Dieng AB, Fall M, Brittain N, Vermaak S, Camara M, Diop-Ndiaye H, Ngom-Gueye NF, Diaw PA, Toure-Kane C, Sow PS, Mboup S, McShane H. Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects. PLoS One. 2013 Jun 28;8(6):e67177. doi: 10.1371/journal.pone.0067177. Print 2013.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MVA85A	Vaccine	1e+08 unknown	Other

A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV

Summary

Timeline

Publications

Drugs

Indications